Hepatocellular MR contrast agents: Enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine

Vogl, 1996, Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA, Radiology, 200, 59, 10.1148/radiology.200.1.8657946 Reimer, 1996, Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence, Radiology, 199, 177, 10.1148/radiology.199.1.8633143 Brasch, 1992, New directions in the development of MR imaging contrast media, Radiology, 183, 1, 10.1148/radiology.183.1.1549653 Morana, 2007, Contrast agents for hepatic MRI, Cancer Imaging, 7 Spec No A, S24, 10.1102/1470-7330.2007.9001 Manfredi, 1998, Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis, J Magn Reson Imaging, 8, 862, 10.1002/jmri.1880080416 van Montfoort, 1999, Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1, J Pharmacol Exp Ther, 290, 153 Ringe, 2010, Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver, AJR Am J Roentgenol, 195, 13, 10.2214/AJR.10.4392 Rohrer, 2005, Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths, Invest Radiol, 40, 715, 10.1097/01.rli.0000184756.66360.d3 McNulty, 1999, Absence of bifurcation of the portal vein, Radiology, 211, 589, 10.1148/radiology.211.2.r99ma10589 Maetani, 1998, Portal vein anomaly associated with deviation of the ligamentum teres to the right and malposition of the gallbladder, Radiology, 207, 723, 10.1148/radiology.207.3.9609896 Gallego, 2002, Congenital and acquired anomalies of the portal venous system, Radiographics, 22, 141, 10.1148/radiographics.22.1.g02ja08141 Filippone, 2010, Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine, J Magn Reson Imaging, 31, 356, 10.1002/jmri.22054 Morana, 2002, Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA, Acad Radiol, 9, S476, 10.1016/S1076-6332(03)80268-4 Hamm, 1995, Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging, Radiology, 195, 785, 10.1148/radiology.195.3.7754011 Reimer, 2004, Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications, Eur Radiol, 14, 559, 10.1007/s00330-004-2236-1 Schuhmann-Giampieri, 1992, Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system, Radiology, 183, 59, 10.1148/radiology.183.1.1549695 Bluemke, 2005, Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study, Radiology, 237, 89, 10.1148/radiol.2371031842 Huppertz, 2004, Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings, Radiology, 230, 266, 10.1148/radiol.2301020269 Feuerlein, 2011, Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein, AJR Am J Roentgenol, 196, W18, 10.2214/AJR.10.4387 Soher, 2007, A review of MR physics: 3T versus 1.5T, Magn Reson Imaging Clin N Am, 15, 10.1016/j.mric.2007.06.002